NGSX - NeurogesX, Inc.

NeurogesX Inc (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Companys commercial product Qutenza, is a dermal delivery system designed to treat certain neuropathic pain conditions and was approved by the United States Food and Drug Administration (FDA) in November 2009 for the management of neuropathic pain associated with postherpetic neuralgia (PHN).